Canaccord Genuity Reiterates Rating on TNGX $TNGX
Key Points
- Canaccord Genuity now rates Tango Therapeutics, Inc. ($TNGX) "buy" with a $42.00 target.
- The Street's average $TNGX price target is $40.45 (Strong Buy).
- $TNGX last traded around $29.81.
Canaccord Genuity reiterated its rating on Tango Therapeutics, Inc. ($TNGX) to a "buy" rating, with a price target of $42.00 in a recent research note.
Tango Therapeutics, Inc. ($TNGX) Stock
Tango Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.